Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Incidence and outcomes of Clostridioides difficile infection in BCMA and CD19 CAR-T cell therapy.

Raj Shah, Fady El Tom, Himil Mahadevia et al. Nov 03, 2025 pp. 7678-7678 10.1182/blood-2025-7678

Abstract Background: Clostridioidesdifficile infection (CDI) represents a significant infectious complication in both Chimeric Antigen Recep...

Synergistic effect of HLA evolutionary divergence and post-transplant biomarkers on non-relapse mortality prediction in adult haploidentical hematopoietic stem cell transplantation

Liping Dou, Di Guan, Yang-Liu Shao et al. Nov 03, 2025 pp. 2474-2474 10.1182/blood-2025-2474

Abstract Background: In hematopoietic stem cell transplantation, post-transplant biomarkers are recognized as reliable prognostic indicators...

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

Colin Stewart, Kevin Hay, Peter Duggan et al. Nov 03, 2025 pp. 2761-2761 10.1182/blood-2025-2761

Abstract Background: Autologous stem cell transplantation (ASCT) remains an important option for patients with late relapses of diffuse larg...

Enhancing CD33.CAR NK cell therapy for acute myeloid leukemia through TGFβ imprinting and NKTR-255

Yanling Liao Yanling Liao, Meijuan Tian, Shaimaa Abdallah et al. Nov 03, 2025 pp. 2330-2330 10.1182/blood-2025-2330

Abstract Background: Acute myeloid leukemia (AML) accounts for 25% of acute leukemias in children and 33% in adults. CD33 is overexpressed i...

Precision In Vivo CAR-T generation via CLAMP-enabled mRNA delivery: Toward scalable and translatable cell therapy

Jingwei Sun, Xi Zhu, Zhao Xu et al. Nov 03, 2025 pp. 103-103 10.1182/blood-2025-103

Abstract Background:Chimeric Antigen Receptor (CAR) T cell therapies have transformed the treatment landscape of hematological malignancies...

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Alex Niu, Alan Hutson, Joseph Parker et al. Nov 03, 2025 pp. 4514-4514 10.1182/blood-2025-4514

Abstract Background: In R/R DLBCL/FL, T-cell engager therapy (TCET) using chimeric antigen receptor T-cell therapy (CART) or bispecific anti...

Good report of secondary allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Myeloid Leukemia

Tong Wu, Zhanxiang Liu, Erhui Yuan et al. Nov 03, 2025 pp. 7795-7795 10.1182/blood-2025-7795

Abstract Objective: Post-transplant relapse in AML was a challenging clinical issue, with limited intervention options currently available....

Real-world implementation of bispecific antibody delivery in community oncology: Overcoming operational barriers through partnerships & interprofessional education

Carmine Deluca, Michael Beyer, Marina Wanes et al. Nov 03, 2025 pp. 4648-4648 10.1182/blood-2025-4648

Abstract Background: T-cell redirecting bispecific antibodies have emerged as a highly effective, off-the-shelf treatmen...

Healthcare resource utilization with prophylactic intravenous anakinra following anti-CD19 CAR-T therapy in B-cell lymphoma: A Canadian single-center quality improvement experience.

Alex Kwan, Irwindeep Sandhu, Peng Wang et al. Nov 03, 2025 pp. 2647-2647 10.1182/blood-2025-2647

Abstract Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed B-cell lymphomas treatment. Its use is complicated b...

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Qiuyu Guo, Zhuo-Yu An, Mengtong Zang et al. Nov 03, 2025 pp. 1413-1413 10.1182/blood-2025-1413

Abstract Introduction Aplastic anemia (AA), a rare disorder characterized by bone marrow failure and pancytopenia, poses exceptionally high...

The incidence of complications related to central venous line placement in patients newly diagnosed with acute lymphoblastic leukemia

Nicholas Manini, Amy Barry, Mackenzie McDougal et al. Nov 03, 2025 pp. 7935-7935 10.1182/blood-2025-7935

Abstract Introduction Central venous lines (CVLs) are crucial to the treatment of acute lymphoblastic leukemia (ALL). They are utilized for...

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Jin Wang, Hongsheng Zhou, Er-Lie Jiang et al. Nov 03, 2025 pp. 5122-5122 10.1182/blood-2025-5122

Abstract Introduction: Inaticabtagene autoleucel (Inati-cel), featuring a CD19 scFv derived from the HI19a clone and a 4-1BB/CD3-ζ costimula...

Anti-TIM3 with hypomethylating agent revives NK and cytotoxic CD4+ T cell activity in patients with AML or MDS

Sofia Forstén, Brittany Ford, Johannes Smolander et al. Nov 03, 2025 pp. 1704-1704 10.1182/blood-2025-1704

Abstract Recent clinical trials in AML combining immune checkpoint inhibitors (anti-PD1, anti-CTLA4) with hypomethylating agents have yielde...

Medical and perioperative management of acute and subacute heparin-induced thrombocytopenia in adults requiring urgent cardiopulmonary bypass surgery.

Jimmy Lee, Allison M. Herzfeld, Maria Paz et al. Nov 03, 2025 pp. 4889-4889 10.1182/blood-2025-4889

Abstract Heparin-induced thrombocytopenia (HIT) is a highly prothrombotic disorder and presents a unique challenge for patients undergoing u...

MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy

Prateek Bhardwaj, Amro Baassiri, Ranjini Sundaram et al. Nov 03, 2025 pp. 322-322 10.1182/blood-2025-322

Abstract Acute Myeloid Leukemia (AML) remains a therapeutically challenging malignancy with poor outcomes. Standard chemotherapy regimens or...

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Dinesh Bhurani, Sharat Damodar, Rohan Halder et al. Nov 03, 2025 pp. 6304-6304 10.1182/blood-2025-6304

Abstract Background: Varnimcabtagene autoleucel (IMN-003A), an autologous second-generation CAR T-cell product with a 4-1BB co-stimulatory d...

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Virginia Tan, Jean Sabile, Amrita Desai et al. Nov 03, 2025 pp. 3372-3372 10.1182/blood-2025-3372

Abstract Introduction: Since the introduction of ABL-specific tyrosine kinase inhibitors (TKI), the prognosis for adults...

Temporal trends in treatment outcomes of acute lymphoblastic leukemia in Japan: Progress and unmet needs

Ryo Koizumi, Aya Nishida, Mika Kuno et al. Nov 03, 2025 pp. 1553-1553 10.1182/blood-2025-1553

Abstract Background The prognosis of acute lymphoblastic leukemia (ALL) has improved globally with advances in diagnostic techniques and the...

Characteristics of the spatio-temporal distributions of chimeric antigen receptor T cells based on real-world evidence

Liting Chen, Man Zhang Nov 03, 2025 pp. 7664-7664 10.1182/blood-2025-7664

Abstract Introduction Chimeric antigen receptor (CAR) T cell therapy, which involves the reinfusion of a patient's T cells into their body a...

Real-world insights into diffuse large B-cell lymphoma from EHR-derived data in Germany and the United Kingdom

Christoph Buhl, Ahmed Sawas, Arun Sujenthiran et al. Nov 03, 2025 pp. 4487-4487 10.1182/blood-2025-4487

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximatel...

Real-world cardiovascular risk of ponatinib in chronic Phase CML: Insights from a nationwide Korean claims-based cohort study

Jeong-Ok Lee, Ju-Hyun Lee, Eun-Jeong Jeong et al. Nov 03, 2025 pp. 1996-1996 10.1182/blood-2025-1996

Abstract Background Ponatinib was introduced relatively late in Korea and has been reimbursed under the national health insurance system sin...

Assessing quality metrics in sickle cell disease: A multicenter review of community hospitals in southwestern Ontario from 2017-2024.

Pedrom Farid, Marco Herrera Quijano, Rong Luo et al. Nov 03, 2025 pp. 7880-7880 10.1182/blood-2025-7880

Abstract Background: In Ontario, Canada, quality standards have been developed to promote the timely and effective management of patients wi...

Multidimensional profiling of dendritic cell and monocyte subsets in sickle cell anemia: Correlation with clinical and inflammatory parameters

Matheus Souza, Izabela Paes, Sara Saad et al. Nov 03, 2025 pp. 2933-2933 10.1182/blood-2025-2933

Abstract Dendritic cells (DCs) and monocytes (Mo) are key components of the innate immune system, playing essential roles in initiating, pol...

Assessing the cost & cost-effectiveness of next-generation sequencing for the diagnosis of hematological malignancies in children, adolescence & young-adults: A systematic literature review

Ella Jeffery, Nancy Bolous, Nickhill Bhakta et al. Nov 03, 2025 pp. 7930-7930 10.1182/blood-2025-7930

Abstract Next-generation sequencing (NGS) is a cumulation of novel diagnostic modalities that can sequence entire parts of a cell in one sam...

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Jorge Cortés, Ehab Atallah, David Andorsky et al. Nov 03, 2025 pp. 906-906 10.1182/blood-2025-906

Abstract Introduction ASC previously demonstrated efficacy, safety, and tolerability in newly diagnosed (1L) CML-CP and CML-CP after ≥2 prio...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page